Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: hepatitis C virus polymerase inhibitors - Medivir/Janssen R&D Ireland

Drug Profile

Research programme: hepatitis C virus polymerase inhibitors - Medivir/Janssen R&D Ireland

Alternative Names: HCV POL discovery project - Medivir/Janssen R&D Ireland

Latest Information Update: 28 Dec 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medivir AB
  • Developer Janssen Infectious Diseases BVBA; Medivir AB
  • Class Nucleosides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 21 Dec 2015 Discontinued - Preclinical for Hepatitis C in Europe (PO)
  • 31 Jul 2015 Preclinical development is underway in Europe
  • 10 Feb 2011 A nucleoside NS5B polymerase inhibitor, TMC 649128, enters into clinical development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top